LEFKOFSKY ERIC P sold $10.5M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 250,000 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $42.06 ($41.34–$42.95, $10.51M total) across 12 trades on 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published Jul 31, 2026, 1:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest actionable element is the disclosed sale size ($10.51M) and post-transaction holdings (200,000 shares). The 10b5-1 designation suggests the trades were scheduled in advance, which typically dampens inference about near-term fundamentals.

02

Market read

This is a primary insider-selling disclosure that may influence short-term sentiment, but it is less likely to drive a fundamental repricing due to the pre-arranged 10b5-1 plan.

03

What to watch

Traders may over-weight insider sales; the key nuance is that the plan was pre-arranged, and the filing does not provide new operational or financial guidance.

Relevance 6/10Novelty 5/10Timing: filed 2026-07-30 for a 2026-07-28 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc. (TEM) by CEO and Chairman Eric P. Lefkofsky, with the sale executed across multiple trades on 2026-07-28.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO and Chairman sold $10.51M of TEM shares via a 10b5-1 plan, leaving 200,000 shares after the sale.

Expected impact

Low to modest near-term sentiment impact; directionally mixed and likely limited given 10b5-1 pre-arrangement.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction size ($10.5M) and timing (2026-07-28), but it explicitly states a pre-arranged 10b5-1 plan, which reduces interpretability as new negative information.

Market effects

Limited sector read-through; this is company-specific insider selling rather than a sector-wide regulatory or demand signal.

No clear regional spillover indicated by the filing details.

No global market linkage beyond Tempus AI-specific sentiment.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity planning rather than bearish expectations, so price impact could be negligible.

Key entities

  • Tempus AI, Inc.

    Subject of the Form 4 insider transaction; CEO and Chairman sold shares under a 10b5-1 plan.

  • LEFKOFSKY ERIC P

    CEO and Chairman, reported indirect open-market sale totaling $10.51M across 12 trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.